Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0066 USD
−3.10 M USD
557.71 K USD
385.86 M
About Provectus Biopharmaceuticals, Inc.
Sector
Industry
CEO
Edward V. Pershing
Website
Headquarters
Knoxville
FIGI
BBG000PGR5K3
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treat several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter on April 1, 2002 and is headquartered in Knoxville, TN.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PVCT is 0.1080 USD — it has decreased by −4.00% in the past 24 hours. Watch Provectus Biopharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Provectus Biopharmaceuticals, Inc. stocks are traded under the ticker PVCT.
PVCT stock has risen by 6.82% compared to the previous week, the month change is a 3.45% rise, over the last year Provectus Biopharmaceuticals, Inc. has showed a −12.90% decrease.
PVCT reached its all-time high on Jul 20, 2000 with the price of 3,150.3150 USD, and its all-time low was 0.0110 USD and was reached on Dec 21, 2016. View more price dynamics on PVCT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PVCT stock is 12.50% volatile and has beta coefficient of −0.54. Track Provectus Biopharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Provectus Biopharmaceuticals, Inc. there?
Today Provectus Biopharmaceuticals, Inc. has the market capitalization of 45.35 M, it has decreased by −0.42% over the last week.
Yes, you can track Provectus Biopharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Provectus Biopharmaceuticals, Inc. is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
PVCT net income for the last quarter is −846.85 K USD, while the quarter before that showed −504.04 K USD of net income which accounts for −68.01% change. Track more Provectus Biopharmaceuticals, Inc. financial stats to get the full picture.
No, PVCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 11, 2024, the company has 4.00 employees. See our rating of the largest employees — is Provectus Biopharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Provectus Biopharmaceuticals, Inc. EBITDA is −2.24 M USD, and current EBITDA margin is −522.95%. See more stats in Provectus Biopharmaceuticals, Inc. financial statements.
Like other stocks, PVCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Provectus Biopharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Provectus Biopharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Provectus Biopharmaceuticals, Inc. stock shows the sell signal. See more of Provectus Biopharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.